Get the Stockscreener App
8.83
2.79%
0.24
Enanta Pharmaceuticals Inc stock is traded at $8.83, with a volume of 119.69K.
It is up +2.79% in the last 24 hours and up +15.12% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$8.59
Open:
$8.61
24h Volume:
119.69K
Relative Volume:
0.72
Market Cap:
$188.77M
Revenue:
$66.59M
Net Income/Loss:
$-104.93M
P/E Ratio:
-1.7838
EPS:
-4.95
Net Cash Flow:
$-96.48M
1W Performance:
+10.38%
1M Performance:
+15.12%
6M Performance:
+9.96%
1Y Performance:
-29.53%
1-Day Range:
$8.47
$9.09
1-Week Range:
$7.91
$9.09
52-Week Range:
$4.09
$13.43
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
8.83 | 174.66M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Enanta files patent suit against Pfizer in Europe - Endpoints News
Pfizer battles another Paxlovid lawsuit from Enanta - Yahoo Finance
Enanta Pharmaceuticals Inc. Rebound Backed by Sentiment Shift2025 Fundamental Recap & Long-Term Growth Plans - beatles.ru
Enanta files EU patent infringement suit against Pfizer - TipRanks
Pfizer sued by Enanta in EU patent fight (ENTA:NASDAQ) - Seeking Alpha
Enanta Pharmaceuticals' Aggressive IP Enforcement Strategy and Its Implications for Long-Term Value Creation - AInvest
Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement - TipRanks
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union | ENTA Stock News - GuruFocus
Enanta files patent infringement suit against Pfizer over Paxlovid - Investing.com
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union - Yahoo Finance
What MACD and RSI say about Enanta Pharmaceuticals Inc.Weekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Real time social sentiment graph for Enanta Pharmaceuticals Inc.Trade Exit Summary & Safe Capital Investment Plans - Newser
Is Enanta Pharmaceuticals Inc. building a consolidation baseBuy Signal & Low Drawdown Trading Strategies - Newser
Applying Elliott Wave Theory to Enanta Pharmaceuticals Inc.2025 Volatility Report & Consistent Growth Stock Picks - Newser
Pattern recognition hints at Enanta Pharmaceuticals Inc. upsideMarket Risk Report & Daily Growth Stock Tips - Newser
Is Enanta Pharmaceuticals Inc. stock bottoming outPortfolio Performance Summary & Capital Protection Trading Alerts - Newser
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsMarket Trend Report & Capital Protection Trade Alerts - Newser
How high can Enanta Pharmaceuticals Inc. stock goJuly 2025 Action & Risk Managed Trade Strategies - Newser
Will Enanta Pharmaceuticals Inc. continue its uptrendJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - Newser
Enanta Pharmaceuticals 15-min chart shows MACD Death Cross and Bollinger Bands Narrowing. - AInvest
Enanta Pharmaceuticals shares rise 1.13% intraday as biotech sector rebounds with record FDA approvals and M&A activity. - AInvest
Understanding the Pharmaceutical and Biotech Industries: A Comprehensive Overview - AInvest
Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener
Can volume confirm reversal in Enanta Pharmaceuticals Inc.Quarterly Earnings Summary & Weekly Momentum Stock Picks - Newser
Sentiment analysis tools applied to Enanta Pharmaceuticals Inc.Trade Performance Summary & Weekly Top Stock Performers List - Newser
Does Enanta Pharmaceuticals Inc. qualify in momentum factor screeningStock Surge & Safe Swing Trade Setup Alerts - Newser
Leading vs lagging indicators on Enanta Pharmaceuticals Inc. performanceWeekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser
How Interest Rate Changes Impact Enanta Pharmaceuticals Inc. Stock PerformanceIPO Watch & Community Verified Trade Signals - Newser
Should I buy Enanta Pharmaceuticals Inc. stock nowJuly 2025 Levels & AI Powered Trade Plan Recommendations - thegnnews.com
Published on: 2025-08-16 05:59:27 - Newser
Enanta Pharmaceuticals Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingJuly 2025 Review & Long Hold Capital Preservation Plans - Newser
Published on: 2025-08-16 14:37:21 - sundaytimes.kr
Enanta Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveMarket Movement Recap & Daily Chart Pattern Signal Reports - Newser
Has Enanta Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewAnalyst Downgrade & Stock Portfolio Risk Control - Newser
Order flow analysis tools used on Enanta Pharmaceuticals Inc.Dollar Strength & Fast Entry High Yield Stock Tips - Newser
Published on: 2025-08-16 00:13:44 - beatles.ru
Enanta's 15min chart triggers Bollinger Bands Narrowing, Bearish Marubozu signals. - AInvest
Enanta Pharmaceuticals: Hold Rating Amid Strategic Advances and Financial Constraints - TipRanks
Detecting price anomalies in Enanta Pharmaceuticals Inc. with AIProfit Target & Fast Gain Swing Trade Alerts - Newser
Enanta Pharmaceuticals' 15-min chart shows RSI overbought and KDJ death cross. - AInvest
Published on: 2025-08-15 02:39:05 - classian.co.kr
Enanta's 15min chart shows KDJ Golden Cross and Bullish Marubozu signals. - AInvest
Enanta's 15-Minute Chart Shows Bollinger Bands Expanding Downward, Bearish Marubozu. - AInvest
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enanta Pharmaceuticals Inc Stock (ENTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
29,305 |
| Luu Brendan | Chief Business Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
36,047 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 06 '24 |
Sale |
8.06 |
866 |
6,980 |
17,918 |
| Or Yat Sun | Chief Scientific Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
369,109 |
| MELLETT PAUL J | Chief Fin. & Admin Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
91,710 |
| Luly Jay R. | President and CEO |
Dec 06 '24 |
Sale |
8.06 |
5,142 |
41,445 |
801,638 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):